Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance dataEric J. Haas, Sharon Alroy‐Preis, Yeheskel Levy et al.|The Lancet|2021Cited by 1.7k
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort studySara Y. Tartof, John M. McLaughlin, Heidi Fischer et al.|The Lancet|2021Cited by 1.3k
Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysisJohn M. McLaughlin, Ann R. Falsey, Luis Jódar et al.|Open Forum Infectious Diseases|2022Cited by 212
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative DesignJohn M. McLaughlin, Luis Jódar, Qin Jiang et al.|Clinical Infectious Diseases|2018Cited by 160
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control studySara Y. Tartof, John M. McLaughlin, Jeff Slezak et al.|The Lancet Respiratory Medicine|2022Cited by 152